180 related articles for article (PubMed ID: 26524539)
1. siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells.
Lu Y; Liu L; Wang Y; Li F; Zhang J; Ye M; Zhao H; Zhang X; Zhang M; Zhao J; Yan B; Yang A; Feng H; Zhang R; Ren X
Biomaterials; 2016 Jan; 76():196-207. PubMed ID: 26524539
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
3. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
4. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
5. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
6. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
[TBL] [Abstract][Full Text] [Related]
8. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
9. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
10. HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.
Lu Y; Wang Y; Zhang M; Liu L; Li F; Zhang J; Ye M; Zhao H; Zhao J; Yan B; Yang A; Zhang R; Li X; Ren X
Oncotarget; 2016 Apr; 7(17):23594-607. PubMed ID: 26988752
[TBL] [Abstract][Full Text] [Related]
11. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
13. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
[TBL] [Abstract][Full Text] [Related]
14. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
16. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
[TBL] [Abstract][Full Text] [Related]
17. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
[TBL] [Abstract][Full Text] [Related]
18. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
19. Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
Togashi Y; Hayashi H; Okamoto K; Fumita S; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
Lung Cancer; 2015 Apr; 88(1):16-23. PubMed ID: 25704955
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]